Human NPY(Neuropeptide Y) ELISA Kit (E-EL-H1893)

This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Human NPY. During the reaction, Human NPY in the sample or standard competes with a fixed amount of Human NPY on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Human NPY. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Human NPY in tested samples can be calculated by comparing the OD of the samples to the standard curve.

Neuropeptide Y (NPY) is a 36-amino-acid amidated peptide and one of the most abundant neuropeptides in the mammalian brain. A member of the pancreatic polypeptide family together with peptide YY and pancreatic polypeptide, it is released together with classical transmitters such as GABA and glutamate, is synthesized as prepro-NPY that is processed to the mature peptide, and is stored in dense-core vesicles for regulated secretion from nerve terminals. NPY acts through G protein-coupled receptors, principally Y1, Y2, Y4 and Y5, that couple to Gi to inhibit adenylyl cyclase and to modulate calcium and potassium channels. In the sympathetic nervous system it is a potent vasoconstrictor, potentiates the action of noradrenaline and promotes adipose tissue growth and angiogenesis, whereas in the hypothalamus it stimulates food intake and fat storage, reduces anxiety and pain perception, suppresses seizure activity and influences circadian rhythms and blood pressure. Altered NPY signaling is implicated in obesity and other metabolic disorders, in anxiety, depression and post-traumatic stress, in hypertension and in epilepsy, and circulating NPY is studied as an index of sympathetic activation. Measurement of NPY supports neuroendocrine research, evaluation of sympathetic nervous activity and investigation of therapeutic strategies that target NPY receptors in metabolic, psychiatric and cardiovascular disease.